Centella AI Therapeutics Angelman Syndrome program

Centella AI Therapeutics is developing an undisclosed therapeutic candidate for the treatment of Angelman Syndrome. Currently in the discovery stage, the program leverages the company's AI-driven platform, which specializes in the identification and optimization of novel small molecule therapeutics. Angelman Syndrome is a rare neurogenetic disorder typically caused by a loss of function of the UBE3A gene, resulting in severe intellectual disability, lack of speech, sleep disturbances, and seizures. As of early 2024, the specific biological target and molecular structure of the lead candidate remain proprietary and have not been publicly disclosed.